INCANNEX HEALTHCARE INC (IXHL) Stock Overview
USA - NASDAQ:IXHL - US45333F1093 - Common Stock
IXHL Key Statistics, Chart & Performance
The current stock price of IXHL is 0.3503 USD. In the past month the price decreased by -32.5%. In the past year, price decreased by -86.47%.
IXHL Latest News, Press Relases and Analysis
IXHL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 51.17 | 782.16B | ||
| JNJ | JOHNSON & JOHNSON | 18.33 | 458.31B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.93 | 260.63B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.59 | 250.00B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.6 | 235.01B | ||
| MRK | MERCK & CO. INC. | 11.43 | 219.80B | ||
| PFE | PFIZER INC | 7.31 | 140.83B | ||
| SNY | SANOFI-ADR | 11.63 | 125.29B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.45 | 88.32B | ||
| GSK | GSK PLC-SPON ADR | 9.78 | 88.09B | ||
| ZTS | ZOETIS INC | 23.72 | 65.38B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.61 | 44.75B |
Related stock screener links
About IXHL
Company Profile
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Company Info
INCANNEX HEALTHCARE INC
8 Century Circuit, Ste. 105, Norwest
New York City NEW SOUTH WALES AU
Employees: 12
Phone: 61409840786
INCANNEX HEALTHCARE INC / IXHL FAQ
Can you describe the business of INCANNEX HEALTHCARE INC?
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. The firm is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
What is the current price of IXHL stock?
The current stock price of IXHL is 0.3503 USD. The price increased by 0.26% in the last trading session.
Does INCANNEX HEALTHCARE INC pay dividends?
IXHL does not pay a dividend.
How is the ChartMill rating for INCANNEX HEALTHCARE INC?
IXHL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
When does INCANNEX HEALTHCARE INC (IXHL) report earnings?
INCANNEX HEALTHCARE INC (IXHL) will report earnings on 2025-11-12.
Who owns INCANNEX HEALTHCARE INC?
You can find the ownership structure of INCANNEX HEALTHCARE INC (IXHL) on the Ownership tab.
What is the Short Interest ratio of INCANNEX HEALTHCARE INC (IXHL) stock?
The outstanding short interest for INCANNEX HEALTHCARE INC (IXHL) is 2.99% of its float.
IXHL Technical Analysis
IXHL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IXHL. The financial health of IXHL is average, but there are quite some concerns on its profitability.
IXHL Financial Highlights
Over the last trailing twelve months IXHL reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -19.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -229.3% | ||
| ROE | -350.18% | ||
| Debt/Equity | 0 |
IXHL Forecast & Estimates
For the next year, analysts expect an EPS growth of -62.5% and a revenue growth 249.95% for IXHL